The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| MIRA | +3.51% | N/A | N/A | -84% |
| S&P | +14.39% | +76.41% | +12.02% | +54% |
MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company engages in developing its product candidate, MIRA1a, as a synthetic cannabinoid analog for treating anxiety & chronic pain by targeting the cannabinoid type 1 and type 2 (CB1 and CB2) receptors. MIRA Pharmaceuticals was founded by Adam Kaplin on September 3, 2020 and is headquartered in Baltimore, MD.
No news articles found for Mira Pharmaceuticals.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | $0.00K | 0.0% |
| Market Cap | $25.93M | 35.0% |
| Market Cap / Employee | $5.19M | 0.0% |
| Employees | 5 | 0.0% |
| Net Income | -$22,694.49K | -1010.4% |
| EBITDA | -$1,316.98K | 36.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $2.64M | -36.3% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00K | 0.0% |
| Short Term Debt | $0.00K | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -477.58% | -308.4% |
| Return On Invested Capital | 152.19% | -127.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$1,096.95K | 40.5% |
| Operating Free Cash Flow | -$1,096.95K | 40.5% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 5.19 | 7.38 | 15.72 | 41.49 | 379.10% |
| Price to Tangible Book Value | 5.19 | 7.38 | 15.72 | 41.49 | 379.13% |
| Enterprise Value to EBITDA | -6.49 | -8.37 | -12.82 | -14.18 | 91.10% |
| Return on Equity | -238.9% | -355.8% | -556.9% | -510.9% | 165.66% |
| Total Debt | $0.00K | $0.00K | $0.00K | $0.00K | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
